2nd Apr 2007 07:01
Beximco Pharmaceuticals Ltd02 April 2007 BEXIMCO PHARMACEUTICALS LTD. 2 April 2007 Beximco Pharmaceuticals Expands African Presence with Commencement of Exports to Ghana Beximco Pharmaceuticals Ltd. ("BPL" or the "Company"), the leadingpharmaceutical manufacturer and the largest pharmaceutical exporter ofBangladesh, has started supplying generic medicines to Ghana. This followsrecent deals with several other African countries making the region anincreasingly important export market for the Company. The first consignment of medicines from BPL included five products, Arixon(R) 1gIV Injection (Ceftriaxone), Arixon(R) 500mg IV Injection (Ceftriaxone), Atrizin(R) Tablet (Cetrizine), Neofloxin(R) 500 Tablet (Ciprofloxacin) and Spanil(R)Tablet (Hyoscine Butyl Bromide). These products will be distributed and marketedby a well-known pharmaceutical distributor in Ghana and are expected to befollowed by several other medicines in the near future. Mr. Nazmul Hassan, CEO of Beximco Pharma said: "Africa has the potential to be an important growth driver in the globalgeneric pharmaceutical market. Beximco now exports pharmaceuticals to Kenya andSomalia in Eastern Africa, Mozambique in South-East Africa and Botswana inSouth-Central Africa. Now, as a part of this strategic expansion in Africa, BPLhas successfully started exporting to Ghana as the first country in WesternAfrica. Success in this market will mark BPL's presence in this region and willspeed up the next phase of its expansion plan in the region." For further enquiries please contact: Beximco Pharma Tel: +880 2 861 9151, ext.2080Nazmul Hassan, CEO Financial Dynamics Tel: +44 (0)20 7269 7169John Gilbert Libertas Capital Tel: +44 (0)20 7569 9650Aamir Quraishi/Andrew Hardy About Beximco Pharmaceuticals Limited Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sellsgeneric pharmaceutical formulation products, active pharmaceutical ingredientsand intravenous fluids. The Company also manufactures and markets its ownbranded generics for almost all diseases. The Company also undertakes contractmanufacturing for multinational pharmaceutical companies. The Company operatesfrom a 20 acre site in Dhaka and currently employs over 2,300 staff. The Company's products are sold to retail outlets, medical institutions andother pharmaceutical manufacturers in Bangladesh, in regional markets such asPakistan, Nepal, Bhutan and Myanmar and in other markets overseas, principallyin East Africa and South East Asia, including Singapore. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Beximco Pharma